Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 39 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 36 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 29 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 33 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 26 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 24 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 22 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 19 relative to control
Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 12 relative to control
Antiobesity activity in C57BL/6 mouse assessed as change in glucose level in blood at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 19 relative to control
Antiobesity activity in C57BL/6 mouse assessed as change in glucose level in blood at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 15 relative to control
Antiobesity activity in C57BL/6 mouse assessed as change in glucose level in blood at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 11 relative to control
Antiobesity activity in C57BL/6 mouse assessed as change in glucose level in blood at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 9 relative to control
Antiobesity activity in C57BL/6 mouse assessed as change in glucose level in blood at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 5 relative to control
Antiobesity activity in C57BL/6 mouse assessed as change in glucose level in blood at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 3 relative to control
Antiobesity activity in C57BL/6 mouse assessed as weight loss at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 19 relative to control
Antiobesity activity in C57BL/6 mouse assessed as weight loss at 5 mg/kg, ip administered on day 1, 4, 5, 7, 17, 15, 19 measured on day 17 relative to control